EHA 2025 Archives - Medical Conferences

Home > Haematology > EHA 2025

European Hematology Association
12–15 June 2025
Milan, Italy

Featured articles

EHA 2025 Highlights Podcast

Presented By

Dr. Rachel Giles, Robert van den Heuvel, Medicom

Conference

EHA 2025

1 July 2025 16:59

Prognostic impact of circulating tumour cells in AL amyloidosis

Presented By

Dr Ioannis Kostopoulos, University of Athens, Greece

Conference

EHA 2025

Type

News article

18 June 2025 11:22

Online First

Unravelling real-world safety and effectiveness of axi-cel in LBCL

Presented By

Dr Dasom Lee, Stanford University, CA, USA

Conference

EHA 2025

Type

News article

18 June 2025 11:23

Prognostic impact of circulating tumour cells in AL amyloidosis

Presented By

Dr Ioannis Kostopoulos, University of Athens, Greece

Conference

EHA 2025

Type

News article

18 June 2025 11:22

Novel investigational gene-editing therapy for TDT and SCD

Presented By

Dr Biao Zheng, BRL Medicine Inc. China

Trial

Phase 1

Conference

EHA 2025

Type

News article

18 June 2025 11:21

inMIND: Positive phase 3 results for tafasitamab combination in FL

Presented By

Prof. Marek Trneny, Charles University, Czech Republic

Trial

Phase 3, inMIND

Conference

EHA 2025

Type

News article

18 June 2025 11:20

ELM-2: Survival benefit for patients with FL on odronextamab

Presented By

Prof. Stefano Luminari, University of Modena and Reggio Emilia, Italy

Trial

Phase 2, ELM-2

Conference

EHA 2025

Type

News article

18 June 2025 11:19

HCT Frailty Scale may refine allo-HCT selection process

Presented By

Dr Maria Queralt Salas, Hospital Clinic de Barcelona, Spain

Conference

EHA 2025

Type

News article

17 June 2025 10:36

Promising safety and efficacy data for novel anti-CD38 treatment in ITP

Presented By

Prof. Yanmei Xu, Peking Union Medical College, China

Trial

Phase 2

Conference

EHA 2025

Type

News article

17 June 2025 10:34

Encouraging results for new mutation-specific targeted therapy in CALR-mutated ET

Presented By

Prof. John Mascarenhas, Mount Sinai, NY, USA

Trial

Phase 1

Conference

EHA 2025

Type

News article

17 June 2025 10:33

RedirecTT-1: Dual antigen-targeting treatment associated with promising efficacy in EMD myeloma

Presented By

Dr Shaji Kumar, Mayo Clinic, MN, USA

Trial

Phase 2, RedirecTT-1

Conference

EHA 2025

Type

News article

17 June 2025 10:30

Large pooled analysis reveals prognostic utility of circulating tumour cells in MM

Presented By

Dr Luca Bertamini, University of Turin, Italy

Conference

EHA 2025

Type

News article

17 June 2025 10:29

GAIA/CLL13: Positive 5-year efficacy outcomes for GIV in CLL

Presented By

Dr Arnon Kater, Amsterdam UMC, the Netherlands

Trial

Phase 3, GAIA, CLL13

Conference

EHA 2025

Type

News article

16 June 2025 10:58

Targeted anti-thymocyte globulin dosing improves transplantation outcomes

Presented By

Prof. Dai-Hong Liu, Fifth Medical Center of PLA General Hospital, Beijing, China

Trial

Phase 3

Conference

EHA 2025

Type

News article

16 June 2025 10:56

TUSCANY: Promising data for addition of tuspetinib in untreated chemo-ineligible AML

Presented By

Dr Gabriel Mannis, Stanford University, CA, USA

Trial

Phase 2, TUSCANY

Conference

EHA 2025

Type

News article

16 June 2025 10:55

MANIFEST-2: Sustained benefits of pelabresib plus ruxolitinib in myelofibrosis

Presented By

Prof. Alessandro Vannucchi, University of Florence, Italy

Trial

Phase 3, MANIFEST-2

Conference

EHA 2025

Type

News article

16 June 2025 10:54

STARGLO: Long-term clinical benefits of Glofit-GemOx over R-GemOx in DLBCL

Presented By

Dr Gareth Gregory, Monash University, Australia

Trial

Phase 3, STARGLO

Conference

EHA 2025

Type

News article

16 June 2025 10:52

Featured articles

CONTENTS

Online First